Suppr超能文献

尿酸转运蛋白基因多态性与 CKD 进展的关系。

Association of a polymorphism in a gene encoding a urate transporter with CKD progression.

机构信息

Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, National Research Council, Institute of Biomedicine and Molecular Biology, Reggio, Calabria, Italy.

Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, National Research Council, Institute of Biomedicine and Molecular Biology, Reggio, Calabria, Italy

出版信息

Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1059-65. doi: 10.2215/CJN.11041013. Epub 2014 Apr 17.

Abstract

BACKGROUND AND OBJECTIVES

Hyperuricemia predicts a high risk for CKD progression but there is no large clinical trial in humans indicating that this relationship is causal in nature. The rs734553 single-nucleotide polymorphism (SNP) of the GLUT9 urate transporter gene was strongly associated with uric acid (UA) levels in a large meta-analysis.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This prospective study adopted the Mendelian randomization approach. The rs734553 SNP was used as an instrumental variable to investigate the relationship between UA and renal outcomes in a cohort of 755 patients with CKD who were enrolled between October 18, 2005, and October 2, 2008. The association between the polymorphism and UA was preliminary confirmed in a series of 211 healthy volunteers enrolled between January 1, 2001, and July 12, 2011, from the same geographic area as the patients with CKD. The study end point was a composite renal-end point (i.e., >30% decrease in the GFR, dialysis, or transplantation). Patients were followed up for a median of 36 months.

RESULTS

In healthy individuals, serum UA levels were highest in homozygotes for the T allele (risk allele), intermediate in heterozygotes for the same allele, and lowest in those without the risk allele (P<0.001), but no such relationship was found in patients with CKD. In the CKD cohort, homozygotes (TT) and heterozygotes (GT) for the risk allele had a 2.35 times higher risk (hazard ratio, 2.35; 95% confidence interval, 1.25 to 4.42; P=0.008) of CKD progression. The risk for CKD progression by rs734553 remained unmodified in analyses adjusting for proteinuria, GFR, and other classical and CKD-peculiar risk factors.

CONCLUSIONS

A GLUT9 polymorphism, which is strongly associated with serum UA levels in healthy individuals of the general population with normal renal function, holds a strong predictive power for CKD progression. These findings are compatible with the hypothesis that the link between UA and CKD progression is causal in nature.

摘要

背景和目的

高尿酸血症预示着 CKD 进展的高风险,但目前尚无大型临床试验表明这种关系具有因果关系。在一项大型荟萃分析中,GLUT9 尿酸转运蛋白基因的 rs734553 单核苷酸多态性(SNP)与尿酸(UA)水平密切相关。

设计、地点、参与者和测量:本前瞻性研究采用孟德尔随机化方法。rs734553 SNP 被用作工具变量,以调查 755 例 CKD 患者队列中 UA 与肾脏结局之间的关系,这些患者于 2005 年 10 月 18 日至 2008 年 10 月 2 日入组。该多态性与 UA 的相关性在 2001 年 1 月 1 日至 2011 年 7 月 12 日期间从同一地理区域招募的 211 例健康志愿者的一系列研究中得到初步证实。研究终点是复合肾脏终点(即,GFR 下降>30%、透析或移植)。中位随访时间为 36 个月。

结果

在健康个体中,携带 T 等位基因(风险等位基因)的纯合子血清 UA 水平最高,携带相同等位基因的杂合子血清 UA 水平居中,而不携带风险等位基因的个体血清 UA 水平最低(P<0.001),但在 CKD 患者中未发现这种关系。在 CKD 队列中,携带风险等位基因的纯合子(TT)和杂合子(GT)发生 CKD 进展的风险增加 2.35 倍(风险比,2.35;95%置信区间,1.25 至 4.42;P=0.008)。在调整蛋白尿、GFR 和其他经典及 CKD 特有的危险因素后,rs734553 对 CKD 进展的风险仍未改变。

结论

在肾功能正常的一般人群中,与健康个体血清 UA 水平密切相关的 GLUT9 多态性对 CKD 进展具有很强的预测能力。这些发现与 UA 与 CKD 进展之间的因果关系假说一致。

相似文献

1
Association of a polymorphism in a gene encoding a urate transporter with CKD progression.
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1059-65. doi: 10.2215/CJN.11041013. Epub 2014 Apr 17.
2
Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression.
Nutr Metab Cardiovasc Dis. 2015 Feb;25(2):167-72. doi: 10.1016/j.numecd.2014.10.016. Epub 2014 Nov 6.
3
A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients.
Nutr Metab Cardiovasc Dis. 2015 Dec;25(12):1087-94. doi: 10.1016/j.numecd.2015.08.004. Epub 2015 Aug 21.
5
A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study.
Am J Kidney Dis. 2015 Feb;65(2):294-302. doi: 10.1053/j.ajkd.2014.07.021. Epub 2014 Oct 7.
6
Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
Am J Kidney Dis. 2015 Dec;66(6):984-92. doi: 10.1053/j.ajkd.2015.06.015. Epub 2015 Jul 21.
7
GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Int J Rheum Dis. 2018 Jun;21(6):1270-1276. doi: 10.1111/1756-185X.13323.
8
Mendelian randomization analysis indicates serum urate has a causal effect on renal function in Chinese women.
Int Urol Nephrol. 2017 Nov;49(11):2035-2042. doi: 10.1007/s11255-017-1686-8. Epub 2017 Aug 30.
9
Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus.
J Diabetes Complications. 2016 Sep-Oct;30(7):1300-7. doi: 10.1016/j.jdiacomp.2016.06.002. Epub 2016 Jun 7.

引用本文的文献

2
Mendelian Randomization Studies: Opening a New Window in the Study of Metabolic Diseases and Chronic Kidney Disease.
Endocr Metab Immune Disord Drug Targets. 2025;25(6):442-457. doi: 10.2174/0118715303288685240808073238.
4
Association of Serum Uric Acid Level with Risk of Abdominal Aortic Calcification: A Large Cross-Sectional Study.
J Inflamm Res. 2023 Apr 26;16:1825-1836. doi: 10.2147/JIR.S404668. eCollection 2023.
5
The Good, the Bad and the New about Uric Acid in Cancer.
Cancers (Basel). 2022 Oct 10;14(19):4959. doi: 10.3390/cancers14194959.
8
Urate Transporters in the Kidney: What Clinicians Need to Know.
Electrolyte Blood Press. 2021 Jun;19(1):1-9. doi: 10.5049/EBP.2021.19.1.1. Epub 2021 Jun 30.
10
Hyperuricemia and chronic kidney disease: to treat or not to treat.
J Bras Nefrol. 2021 Oct-Dec;43(4):572-579. doi: 10.1590/2175-8239-JBN-2020-U002.

本文引用的文献

1
APOL1 risk variants, race, and progression of chronic kidney disease.
N Engl J Med. 2013 Dec 5;369(23):2183-96. doi: 10.1056/NEJMoa1310345. Epub 2013 Nov 9.
2
Urate transporters in the genomic era.
Curr Opin Nephrol Hypertens. 2013 Sep;22(5):545-50. doi: 10.1097/MNH.0b013e328363ffc8.
3
Uric acid and chronic kidney disease: which is chasing which?
Nephrol Dial Transplant. 2013 Sep;28(9):2221-8. doi: 10.1093/ndt/gft029. Epub 2013 Mar 29.
4
Renal transport of uric acid: evolving concepts and uncertainties.
Adv Chronic Kidney Dis. 2012 Nov;19(6):358-71. doi: 10.1053/j.ackd.2012.07.009.
5
Genotype-based changes in serum uric acid affect blood pressure.
Kidney Int. 2012 Mar;81(5):502-7. doi: 10.1038/ki.2011.414. Epub 2011 Dec 21.
6
Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.
Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93. doi: 10.2215/CJN.01580210. Epub 2010 Jun 10.
7
Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population.
Am J Med Sci. 2010 Jun;339(6):509-15. doi: 10.1097/MAJ.0b013e3181db6e16.
8
Association of uric acid with change in kidney function in healthy normotensive individuals.
Am J Kidney Dis. 2010 Aug;56(2):264-72. doi: 10.1053/j.ajkd.2010.01.019. Epub 2010 Apr 10.
9
Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy.
Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15501-6. doi: 10.1073/pnas.0904411106. Epub 2009 Aug 21.
10
Uric acid: a novel mediator and marker of risk in chronic kidney disease?
Curr Opin Nephrol Hypertens. 2009 Nov;18(6):526-30. doi: 10.1097/MNH.0b013e328330d9d0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验